Ken Griffin Y M Abs Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 19,400 shares of YMAB stock, worth $251,230. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,400
Previous 10,600
83.02%
Holding current value
$251,230
Previous $172,000
36.05%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding YMAB
# of Institutions
96Shares Held
23.8MCall Options Held
19.4KPut Options Held
300-
Paradigm Biocapital Advisors LP New York, NY3.87MShares$50.1 Million1.89% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$38.1 Million0.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$28.4 Million1.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.96MShares$25.3 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X01.83MShares$23.7 Million0.13% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $566M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...